Tags

Type your tag names separated by a space and hit enter

Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.
J Clin Lab Immunol. 1992 Jan; 37(1):21-37.JC

Abstract

We investigated the effect of PSK, a protein-bound polysaccharide obtained from Coriolus versicolor of basidiomycetes, on antitumor immunity in tumor-bearing mice. PSK prolonged significantly the life span of C3H/He mice bearing syngeneic plasmacytoma X5563 in a schedule- and dose-dependent manner. PSK was most effective when administered at 100 mg/kg every other day ten times starting from the day after tumor inoculation. The administration of PSK enhanced significantly the cytostatic activity of peritoneal exudate plastic-adherent cells and the cytolytic activity of spleen cells after in vitro incubation with mitomycin C-treated tumor cells. In addition, PSK restored the cytokine-producing capacity of spleen cells suppressed in tumor-bearing mice after in vitro incubation with mitogen. Sera from tumor-bearing mice suppressed the activity of such effector cells as well as the interleukin 2-producing capacity of spleen cells, but sera from PSK-treated tumor-bearing mice prevented this suppression. These results suggest that PSK enhances antitumor immunity by reducing immunosuppressive activity of serum from tumor-bearing mice.

Authors+Show Affiliations

Matsunaga K
Biomedical Research Laboratories, Kureha Chemical Industry, Co., Ltd., Tokyo, Japan.
Iijima H
No affiliation info available
Aota M
No affiliation info available
Oguchi Y
No affiliation info available
Fujii T
No affiliation info available
Yoshikumi C
No affiliation info available
Nomoto K
No affiliation info available

MeSH

Adjuvants, ImmunologicAnimalsAscitesCytokinesCytotoxicity, ImmunologicDose-Response Relationship, DrugFemaleImmunologic FactorsLymphocyte ActivationMiceMice, Inbred C3HNeoplasm TransplantationPlasmacytomaProteoglycansSpleenT-Lymphocyte Subsets

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1339233

Citation

Matsunaga, K, et al. "Enhancement of Effector Cell Activities in Mice Bearing Syngeneic Plasmacytoma X5563 By a Biological Response Modifier, PSK." Journal of Clinical & Laboratory Immunology, vol. 37, no. 1, 1992, pp. 21-37.
Matsunaga K, Iijima H, Aota M, et al. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK. J Clin Lab Immunol. 1992;37(1):21-37.
Matsunaga, K., Iijima, H., Aota, M., Oguchi, Y., Fujii, T., Yoshikumi, C., & Nomoto, K. (1992). Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK. Journal of Clinical & Laboratory Immunology, 37(1), 21-37.
Matsunaga K, et al. Enhancement of Effector Cell Activities in Mice Bearing Syngeneic Plasmacytoma X5563 By a Biological Response Modifier, PSK. J Clin Lab Immunol. 1992;37(1):21-37. PubMed PMID: 1339233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK. AU - Matsunaga,K, AU - Iijima,H, AU - Aota,M, AU - Oguchi,Y, AU - Fujii,T, AU - Yoshikumi,C, AU - Nomoto,K, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 21 EP - 37 JF - Journal of clinical & laboratory immunology JO - J Clin Lab Immunol VL - 37 IS - 1 N2 - We investigated the effect of PSK, a protein-bound polysaccharide obtained from Coriolus versicolor of basidiomycetes, on antitumor immunity in tumor-bearing mice. PSK prolonged significantly the life span of C3H/He mice bearing syngeneic plasmacytoma X5563 in a schedule- and dose-dependent manner. PSK was most effective when administered at 100 mg/kg every other day ten times starting from the day after tumor inoculation. The administration of PSK enhanced significantly the cytostatic activity of peritoneal exudate plastic-adherent cells and the cytolytic activity of spleen cells after in vitro incubation with mitomycin C-treated tumor cells. In addition, PSK restored the cytokine-producing capacity of spleen cells suppressed in tumor-bearing mice after in vitro incubation with mitogen. Sera from tumor-bearing mice suppressed the activity of such effector cells as well as the interleukin 2-producing capacity of spleen cells, but sera from PSK-treated tumor-bearing mice prevented this suppression. These results suggest that PSK enhances antitumor immunity by reducing immunosuppressive activity of serum from tumor-bearing mice. SN - 0141-2760 UR - https://www.unboundmedicine.com/medline/citation/1339233/Enhancement_of_effector_cell_activities_in_mice_bearing_syngeneic_plasmacytoma_X5563_by_a_biological_response_modifier_PSK_ DB - PRIME DP - Unbound Medicine ER -